Actively Recruiting
Phase 1 Study to Evaluate Safety and Immune Response of the TB Vaccine QTP101 ID93GLA-SE in Adults Aged 55 to 74 Who Have Been Vaccinated with BCG
Led by Quratis Inc. · Updated on 2025-06-17
144
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and immune response of the investigational tuberculosis vaccine candidate QTP101 ID93GLA-SE in older adults aged 55 to 74 years who have received the BCG vaccine. This Phase 1 randomized, double-blind, placebo-controlled trial includes participants with either positive or negative QuantiFERON-TB QFT test results, aiming to address the high risk of TB in aging populations. The study explores how the vaccine stimulates the immune system and assesses safety to guide future vaccine development. Participants are randomly assigned to one of three groups receiving either a low dose or high dose of QTP101 or a placebo. Each participant receives three intramuscular injections on Day 0, Day 28, and Day 56. The study includes specific age groups 55-64 and 65-74 years and monitors safety carefully, especially in older adults, using a sentinel subgroup approach. Follow-up includes regular visits at 1, 6, and 12 months after the final injection. During the study, participants undergo multiple blood draws to measure antibody levels and immune cell responses before vaccination and at several time points up to 48 weeks after the last dose. Safety is monitored through assessments of adverse events, physical exams, vital signs, and laboratory tests from the screening phase until 12 months post-vaccination. The trial collects detailed data to evaluate both the vaccines safety profile and its ability to trigger protective immune responses over time.
CONDITIONS
Brief Title
ID93+GLA-SE Vaccine Against Tuberculosis in Older Adults Aged 55-74
Research Team
J
Jinhee Lee, DVM, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here